Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes

Masamitsu Yanada, Shohei Mizuno, Satoshi Yamasaki, Kaito Harada, Takaaki Konuma, Hiroya Tamaki, Naoki Shingai, Naoyuki Uchida, Yukiyasu Ozawa, Masatsugu Tanaka, Makoto Onizuka, Masashi Sawa, Hirohisa Nakamae, Souichi Shiratori, Ken ichi Matsuoka, Tetsuya Eto, Toshiro Kawakita, Yumiko Maruyama, Tatsuo Ichinohe, Yoshinobu KandaYoshiko Atsuta, Jun Aoki, Shingo Yano

Research output: Contribution to journalArticlepeer-review

Abstract

To evaluate whether outcomes following allogeneic hematopoietic cell transplantation differ according to disease type, a three-way comparison for patients with de novo acute myeloid leukemia (AML) (n = 3318), AML evolving from myelodysplastic syndromes (MDS) (n = 208), and MDS with excess blasts (MDS-EB) (n = 994) was performed. The 5-year probabilities of overall survival (OS) for de novo AML, AML evolving from MDS, and MDS-EB were 60%, 42%, and 41% (p < 0.001), respectively. Multivariate analysis revealed that, compared to de novo AML, AML evolving from MDS was associated with a higher risk of NRM (p = 0.030) and MDS-EB with a higher risk of relapse (p < 0.001), both leading to lower OS (p = 0.010 and p < 0.001, respectively). These findings demonstrate inter-disease differences in post-transplant outcomes and highlight the needs to reduce NRM for AML evolving from MDS and to reduce relapse for MDS-EB.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - 2021

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this